Pfizer mCRC Program Update Clinical Development Plan 2023

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Pfizer presents an update on its metastatic colorectal cancer (mCRC) program and clinical development strategy. The company outlines expectations for clinical data from its first-line RAS-mutated mCRC trial, anticipated in mid-2024. This investor presentation details progress in oncology pipeline development and therapeutic advancement.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Pfizer

View all →

Pfizer 2016 Global Healthcare Conference Presentation

conference

8 Pages

Pfizer 2022 Near-Term Launches High-Value Pipeline

investor_presentation

Similar investor_presentations from other companies

Browse all →

EOG Resources 4Q 2016 Investor Presentation

investor_presentation

45 Pages

EOG Resources

Intuitive Surgical Investor Presentation — September 2020

investor_presentation